{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:31:22Z","timestamp":1707525082178},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,27]]},"DOI":"10.7759\/cureus.39571","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T17:32:33Z","timestamp":1685208753000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case Report of SMARCA4-Deficient Thoracic Sarcoma: A Rare and Aggressive Disease With a Grim Prognosis"],"prefix":"10.7759","author":[{"given":"Siham","family":"Lalaoui Rachidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Firmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Elfadli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Essadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.1038\/ng.3399","article-title":"SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas","volume":"47","author":"Le Loarer F","year":"2015","unstructured":"Le Loarer F, Watson S, Pierron G, et al.. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015, 47:1200-5.","journal-title":"Nat Genet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.11","article-title":"Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities","volume":"30","author":"Yoshida A","year":"2017","unstructured":"Yoshida A, Kobayashi E, Kubo T, et al.. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017, 30:797-809. 10.1038\/modpathol.2017.11","journal-title":"Mod Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.023","article-title":"SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas","volume":"15","author":"Rekhtman N","year":"2020","unstructured":"Rekhtman N, Montecalvo J, Chang JC, et al.. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020, 15:231-47. 10.1016\/j.jtho.2019.10.023","journal-title":"J Thorac Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.61","article-title":"SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior","volume":"30","author":"Sauter JL","year":"2017","unstructured":"Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017, 30:1422-32. 10.1038\/modpathol.2017.61","journal-title":"Mod Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1273","article-title":"The SWI\/SNF complex--chromatin and cancer","volume":"4","author":"Roberts CW","year":"2004","unstructured":"Roberts CW, Orkin SH. The SWI\/SNF complex--chromatin and cancer. Nat Rev Cancer. 2004, 4:133-42. 10.1038\/nrc1273","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch C","year":"2013","unstructured":"Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR. Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013, 45:592-601. 10.1038\/ng.2628","journal-title":"Nat Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30708","article-title":"SMARCA4-deficient undifferentiated tumor: a rare malignancy with distinct clinicopathological characteristics","volume":"14","author":"Al-Shbool G","year":"2022","unstructured":"Al-Shbool G, Krishnan Nair H. SMARCA4-deficient undifferentiated tumor: a rare malignancy with distinct clinicopathological characteristics. Cureus. 2022, 14:e30708. 10.7759\/cureus.30708","journal-title":"Cureus"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.005","article-title":"The new WHO classification of lung tumors","volume":"16","author":"Tsao M","year":"2021","unstructured":"Tsao M. The new WHO classification of lung tumors. J Thorac Oncol. 2021, 16:63.","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11748-021-01627-z","article-title":"SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma","volume":"69","author":"Khanchel F","year":"2021","unstructured":"Khanchel F, Hedhili R, Zenaidi H, et al.. SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma. Gen Thorac Cardiovasc Surg. 2021, 69:1155-8. 10.1007\/s11748-021-01627-z","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.230","article-title":"Claudin-4 expression distinguishes SWI\/SNF complex-deficient undifferentiated carcinomas from sarcomas","volume":"30","author":"Schaefer IM","year":"2017","unstructured":"Schaefer IM, Agaimy A, Fletcher CD, Hornick JL. Claudin-4 expression distinguishes SWI\/SNF complex-deficient undifferentiated carcinomas from sarcomas. Mod Pathol. 2017, 30:539-48. 10.1038\/modpathol.2016.230","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0142","article-title":"Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report","volume":"12","author":"Iijima Y","year":"2020","unstructured":"Iijima Y, Sakakibara R, Ishizuka M, et al.. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report. Immunotherapy. 2020, 12:563-9. 10.2217\/imt-2019-0142","journal-title":"Immunotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13215","article-title":"Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report","volume":"10","author":"Takada K","year":"2019","unstructured":"Takada K, Sugita S, Murase K, et al.. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report. Thorac Cancer. 2019, 10:2312-5. 10.1111\/1759-7714.13215","journal-title":"Thorac Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14547","article-title":"SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: a case report","volume":"13","author":"Utsumi T","year":"2022","unstructured":"Utsumi T, Taniguchi Y, Noda Y, Fukai M, Kibata K, Murakawa T. SMARCA4-deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: a case report. Thorac Cancer. 2022, 13:2264-6. 10.1111\/1759-7714.14547","journal-title":"Thorac Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac040","article-title":"Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors","volume":"27","author":"Gantzer J","year":"2022","unstructured":"Gantzer J, Davidson G, Vokshi B, et al.. Immune-desert tumor microenvironment in thoracic SMARCA4-deficient undifferentiated tumors with limited efficacy of immune checkpoint inhibitors. Oncologist. 2022, 27:501-11. 10.1093\/oncolo\/oyac040","journal-title":"Oncologist"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1605905","article-title":"Remodeling the cancer epigenome: mutations in the SWI\/SNF complex offer new therapeutic opportunities","volume":"19","author":"Orlando KA","year":"2019","unstructured":"Orlando KA, Nguyen V, Raab JR, Walhart T, Weissman BE. Remodeling the cancer epigenome: mutations in the SWI\/SNF complex offer new therapeutic opportunities. Expert Rev Anticancer Ther. 2019, 19:375-91. 10.1080\/14737140.2019.1605905","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1703966114","article-title":"PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI\/SNF mutant tumors","volume":"114","author":"Januario T","year":"2017","unstructured":"Januario T, Ye X, Bainer R, et al.. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI\/SNF mutant tumors. Proc Natl Acad Sci U S A. 2017, 114:12249-54. 10.1073\/pnas.1703966114","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2020.e00231","article-title":"SMARCA4-deficient uterine sarcoma: a case report and a concise review","volume":"27","author":"Kord A","year":"2020","unstructured":"Kord A, Eppurath A, Drammeh H, Elbaz Younes I, Xie KL. SMARCA4-deficient uterine sarcoma: a case report and a concise review. Case Rep Womens Health. 2020, 27:e00231. 10.1016\/j.crwh.2020.e00231","journal-title":"Case Rep Womens Health"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi NA","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, et al.. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015, 348:124-8. 10.1126\/science.aaa1348","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0311","article-title":"Atezolizumab with bevacizumab, paclitaxel\u00a0and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma","volume":"13","author":"Kawachi H","year":"2021","unstructured":"Kawachi H, Kunimasa K, Kukita Y, et al.. Atezolizumab with bevacizumab, paclitaxel\u00a0and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma. Immunotherapy. 2021, 13:799-806. 10.2217\/imt-2020-0311","journal-title":"Immunotherapy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/151227-a-case-report-of-smarca4-deficient-thoracic-sarcoma-a-rare-and-aggressive-disease-with-a-grim-prognosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:47Z","timestamp":1707508967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/151227-a-case-report-of-smarca4-deficient-thoracic-sarcoma-a-rare-and-aggressive-disease-with-a-grim-prognosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.39571","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,27]]}}}